Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. (Q51488952)
Jump to navigation
Jump to search
scientific article published in November 1998
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. |
scientific article published in November 1998 |
Statements
Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. (English)
1 reference
Arlander E
1 reference
Ekström G
1 reference
Alm C
1 reference
Carrillo JA
1 reference
Bielenstein M
1 reference
Böttiger Y
1 reference
Bertilsson L
1 reference
1 November 1998
1 reference
64
1 reference
5
1 reference
484-491
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference